多西他赛联合雄激素受体轴靶向治疗与雄激素剥夺治疗用于转移性激素敏感性前列腺癌:网状Meta分析
该网状Meta分析纳入11项随机对照试验(n=11546),比较ADT联合ARAT与三联疗法(ADT+ARAT+多西他赛)在转移性激素敏感性前列腺癌中的疗效。三联疗法较ADT联合ARAT的总生存获益未达统计学显著(HR 0.89,95%CI 0.68-1.16),但P-score排序三联疗法最高(0.936),成为最佳治疗策略的可能性为77%。
要点
- 三联疗法较ADT联合ARAT的OS获益未达统计学显著(HR 0.89,95%CI 0.68-1.16)。
- ADT联合多西他赛(HR 1.16,95%CI 0.94-1.43)和ADT单药(HR 1.46,95%CI 1.30-1.64)死亡风险增加。
- P-score排序三联疗法最高(0.936),成为最佳策略可能性77%。
核心结论
- 三联疗法(ADT+ARAT+多西他赛)是排名最高的治疗策略,但较ADT联合ARAT未带来统计学显著的OS获益。
研究设计与样本
- 网状Meta分析,纳入11项随机对照试验,共11546例转移性激素敏感性前列腺癌患者。
主要发现
- 与ADT联合ARAT相比,三联疗法的OS获益未达统计学显著(HR 0.89,95%CI 0.68-1.16)。
- 与ADT联合ARAT相比,ADT联合多西他赛的死亡风险增加(HR 1.16,95%CI 0.94-1.43),ADT单药的死亡风险增加(HR 1.46,95%CI 1.30-1.64)。
- P-score排序:三联疗法0.936,ADT联合ARAT 0.704。
- 三联疗法成为最佳治疗策略的可能性为77%,ADT联合ARAT为23%。
关键数值与推荐
- 主要终点为总生存(OS)。
- 采用标准随机效应网状Meta分析和贝叶斯分析比较ADT联合ARAT与三联疗法。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Randomized controlled trials (RCTs) have shown that addition of docetaxel or androgen receptor axis-targeted therapy (ARAT) to androgen deprivation therapy (ADT) or addition of ARAT to ADT and docetaxel improves overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC). However, it is unknown whether docetaxel, when given as part of triplet therapy, has an independent OS benefit. OBJECTIVE: To compare the efficacy of ADT plus ARAT with the triplet of ADT, ARAT, and docetaxel through a network meta-analysis (NMA) of RCTs in mHSPC. EVIDENCE ACQUISITION: Bibliographic databases and conference proceedings were searched in March 2022 for RCTs that evaluated the addition of docetaxel, ARAT, or both to ADT in mHSPC. The primary endpoint was OS. Standard random-effect NMA and Bayesian analyses were performed to compare ADT plus ARAT with triplet therapy. EVIDENCE SYNTHESIS: Eleven RCTs (n = 11 546) were eligible. Compared with ADT plus ARAT, the triplet had a nonsignificant OS benefit (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.68-1.16), while ADT plus docetaxel (HR 1.16 [0.94-1.43]) and ADT alone (HR 1.46 [1.30-1.64]) had an increased risk of death. By P-score ordering, the triplet was the most effective treatment strategy (P score = 0.936) followed by ADT plus ARAT (P score = 0.704). The triplet had a 77% likelihood of being the best treatment strategy compared with a 23% likelihood for ADT plus ARAT. CONCLUSIONS: The triplet of ADT, ARAT, and docetaxel was the highest ranked treatment strategy, but it did not confer a statistically significant OS benefit over ADT plus ARAT. This NMA provides the highest-level comparative evidence for these treatment approaches in the initial management of mHSPC. PATIENT SUMMARY: We synthesized the available evidence from clinical trials conducted in newly diagnosed metastatic prostate cancer to compare the survival of patients receiving triplet therapy (androgen receptor axis-targeted therapy [ARAT], androgen deprivation therapy [ADT], and docetaxel) with those receiving only ARAT and ADT. We conclude that the triplet is a somewhat more effective treatment approach.
引用
- Roy S, Sayyid R, Saad F, et al. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. Eur Urol Oncol. 2022. PMID: 35811293. doi:10.1016/j.euo.2022.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。